Vesicular acetylcholine transporter (VAChT) in the brain of spontaneously hypertensive rats (SHR): Effect of treatment with an acetylcholinesterase inhibitor

Clinical and Experimental Hypertension

Volumn 30, Issue 8, 2008, Pages 732-743

  Tayebati, S K ^a,b   Di Tullio, M A ^a   Amenta, F ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b Section of Human Anatomy   (Italy)

Author keywords

Adult onset disorders; Cerebral areas; Cholinergic system; Hypertension; VAChT; Vascular dementia

Indexed keywords

BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; GALANTAMINE; VESICULAR ACETYLCHOLINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN DAMAGE; CHOLINERGIC TRANSMISSION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; HYPERTENSION; IMMUNOHISTOCHEMISTRY; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BRAIN; CEREBELLUM; CEREBRAL CORTEX; CHOLINERGIC FIBERS; CHOLINESTERASE INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GALANTAMINE; HIPPOCAMPUS; HYPERTENSION; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SYNAPTIC TRANSMISSION; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS;

EID: 56549093564     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960802580216     Document Type: Conference Paper

References (40)

1. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: A neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22:273-280.
2. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol. 2000;163:495-529.
3. Tayebati SK. Animal models of cognitive dysfunction. Mech Ageing Develop 2006;127:100-108.
4. Birkenhager WH, Staessen JA. Progress in cardiovascular diseases cognitive function in essential hypertension. Prog Cardiovasc Dis. 2006;49:1-10.
5. Frishman WH. Are antihypertensive agents protective against dementia? A review of clinical and preclinical data. Heart Dis. 2002;4:380-386.
6. Jellinger KA. Vascular-ischemic dementia: An update. J Neural Transm. 2002; 62 (Suppl.): 1-23.
7. Kaye JA. Diagnostic challenges in dementia. Neurology 1998; 51(1 Suppl. 1):, S45-S52; discussion S65-S67.
8. Bowler JV, Steenhuis R, Hachinski V. Conceptual background to vascular cognitive impairment. Alzheimer Dis Assoc Disord. 1999;13 (Suppl. 3):S30-S37.
9. Roman GC. Vascular dementia: A historical background. Int Psychogeriatr. 2003;15 (Suppl. 1):3-11.
10. Roman GC. Cholinergic dysfunction in vascular dementia. Curr Psychiatry Rep. 2005;7:18-26.
11. Blusztajn JK, Wurtman RJ. Choline and cholinergic neurons. Science. 1983;221:614-620.
12. Tucek S. The synthesis of acetylcholine: Twenty years of progress. Prog Brain Res. 1990;84:467-477.
13. Weihe E, Tao-Cheng JH, Schafer MK, Erickson JD, Eiden LE. Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles. Proc Natl Acad Sci USA. 1996;93:3547-3552.
14. Roghani A, Shirzadi A, Kohan SA, Edwards RH, Butcher LL. Differential distribution of the putative vesicular transporter for acetylcholine in the rat central nervous system. Brain Res Mol Brain Res. 1996;43:65-76.
15. Ichikawa T, Ajiki K, Matsuura J, Misawa H. Localization of two cholinergic markers, choline acetyltransferase and vesicular acetylcholine transporter in the central nervous system of the rat: In situ hybridization histochemistry and immunohistochemistry. J Chem Neuroanat. 1997;13:23-39.
16. Amenta F, Di Tullio MA, Tomassoni D. Arterial hypertension and brain damage - evidence from animal models. Clin Exp Hypertens. 2003;25:359-380.
17. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 4th ed. New York: Academic Press; 1998.
18. Amenta F, Bronzetti E, Cantalamessa F, El-Assouad D, Felici L, Ricci A, Tayebati SK. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J Neuroimmunol, 2001;117:133-142.
19. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA. 1979;76:4350-4354.
20. Gerfen CR. The neostriatal mosaic: Multiple levels of compartmental organization. Trends Neurosci. 1992;15:133-139.
21. Amenta F, Mancini M, Naves FJ, Vega JA, Zaccheo D. Effect of treatment with the dihydropyridine-type calcium antagonist darodipine (PY 108-068) on the expression of calbindin D-28K immunoreactivity in the cerebellar cortex of aged rats. Mech Ageing Dev. 1995;77:149-157.
22. Roghani A, Feldman J, Kohan SA, Shirzadi A, Gundersen CB, Brecha N, Edwards RH. Molecular cloning of putative vesicular transporter for acetylcholine. Proc Natl Acad Sci USA. 1994;91:10620-10624.
23. Bando K, Naganuma T, Taguchi K, Ginoza Y, Tanaka Y, Koike K, Takatoku K. Piperazine analog of vesamicol: In vitro and in vivo characterization for vesicular acetylcholine transporter. Synapse. 2000;38:27-37.
24. Efange SM. In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter. FASEB J. 2000;14:2401-2413.
25. Tayebati SK, Di Tullio MA, Amenta F. Effect of treatment with the cholinesterase inhibitor rivastigmine on vesicular acetylcholine transporter and choline acetyl transferase in rat brain. Clin Exp Hyperten. 2004;26:363-373.
26. Lis CG, Gaviria M. Vascular dementia, hypertension, and the brain. Neurol Res. 1997;19: 471-480.
27. Tabei R. On histochemical studies of the various organs of spontaneously hypertensive rats. Jpn Circ J. 1966;30:717-742.
28. Lawrence AD, Sahakian BJ. Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord. 1995;9 (Suppl. 2):43-49.
29. Rabey JM, Neufeld MY, Treves TA, Sifris P, Korczyn AD Cognitive effects of scopolamine in dementia. J Neural Transm. 1996;103:873-881.
30. Jope RS, Song L, Powers RE. Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain. Neurobiol Aging. 1997;18:111-120.
31. Sabbagh MN, Reid RT, Corey-Bloom J, Rao TS, Hansen LA, Alford M, Masliah E, Adem A, Lloyd GK, Thal LJ. Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease. J Neural Transmission. 1998;105:709-717.
32. Arvidsson U, Riedl M, Elde R, Meister B. Vesicular acetylcholine transporter (VAChT) protein: A novel and unique marker for cholinergic neurons in the central and peripheral nervous systems. J Comp Neurol. 1997;378:454-467.
33. Hu L, Wong TP, Cote SL, Bell KF, Cuello AC. The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in Alzheimer's disease-like transgenic mice. Neuroscience. 2003;121:421-432.
34. Gattu M, Pauly JR, Urbanawiz S, Buccafusco JJ. Autoradiographic comparison of muscarinic M1 and M2 binding sites in the CNS of spontaneously hypertensive and normotensive rats. Brain Res. 1997;771:173-183.
35. Gattu M, Pauly JR, Boss KL, Summers JB, Buccafusco JJ. Cognitive impairment in spontaneously hypertensive rats: Role of central nicotinic receptors, I. Brain Res. 1997;771:89-103.
36. Harvey AL. The pharmacology of galanthamine and its analogues. Pharmacol Ther. 1995;68:113-128.
37. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-155.
38. Ikonomovic MD, Mufson EJ, Cochran EJ, Bennett DA, DeKosky ST. Acetylcholinesterase changes in people with mild cognitive impairment: implications for hippocampal plasticity. Soc Neurosci Abstr Program. 2002; #882.6.
39. Hernandez CM, Gearhart DA, Parikh V, Hohnadel EJ, Davis LW, Middlemore ML, Warsi SP, Waller JL, Terry AV Jr. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. J Pharmacol Exp Therapeutics. 2006;316:679-694.
40. Terry AV Jr, Hernandez CM, Buccafusco JJ, Gattu M. Deficits in spatial learning and nicotinic-acetylcholine receptors in older, spontaneously hypertensive rats. Neuroscience. 2000;101:357-368.